Quick Answer
ACADIA PHARMACEUTICALS INC reported Net Income Loss of $391.00 million for the year ending 2025.
- ACADIA PHARMACEUTICALS INC showed an increase of +72.7% in Net Income Loss from 2024 to 2025.
- This data is from ACADIA PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: -$40.38 million | Q2 2015: -$39.38 million | Q3 2015: -$38.91 million | Q4 2015: -$45.78 million | Q1 2016: -$49.76 million | Q2 2016: -$71.32 million | Q3 2016: -$71.61 million | Q4 2016: -$78.70 million | Q1 2017: -$87.84 million | Q2 2017: -$67.44 million | Q3 2017: -$65.25 million | Q4 2017: -$68.87 million | Q1 2018: -$54.30 million | Q2 2018: -$63.27 million | Q3 2018: -$62.14 million | Q4 2018: -$65.49 million | Q1 2019: -$85.30 million | Q2 2019: -$54.94 million | Q3 2019: -$41.98 million | Q4 2019: -$53.04 million | Q1 2020: -$88.02 million | Q2 2020: -$42.14 million | Q3 2020: -$84.66 million | Q4 2020: -$66.76 million | Q1 2021: -$66.45 million | Q2 2021: -$43.87 million | Q3 2021: -$14.46 million | Q4 2021: -$43.09 million | Q1 2022: -$113.06 million | Q2 2022: -$34.01 million | Q3 2022: -$27.18 million | Q4 2022: -$41.73 million | Q1 2023: -$43.02 million | Q2 2023: $1.11 million | Q3 2023: -$65.18 million | Q4 2023: $45.80 million | Q1 2024: $16.56 million | Q2 2024: $33.39 million | Q3 2024: $32.77 million | Q1 2025: $18.99 million | Q2 2025: $26.67 million | Q3 2025: $71.78 million.
- Over the full 17 years of available data (2009 to 2025), ACADIA PHARMACEUTICALS INC's Net Income Loss has grown by 966.1%.
- Historical annual values: Fiscal year 2025: $391.00 million | Fiscal year 2024: $226.45 million | Fiscal year 2023: -$61.29 million | Fiscal year 2022: -$215.98 million | Fiscal year 2021: -$167.87 million | Fiscal year 2020: -$281.58 million | Fiscal year 2019: -$235.26 million | Fiscal year 2018: -$245.19 million | Fiscal year 2017: -$289.40 million | Fiscal year 2016: -$271.39 million | Fiscal year 2015: -$164.44 million | Fiscal year 2014: -$92.48 million | Fiscal year 2013: -$37.95 million | Fiscal year 2012: -$20.85 million | Fiscal year 2011: -$22.77 million | Fiscal year 2010: $15.14 million | Fiscal year 2009: -$45.15 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: